# CER-001 Atherosclerosis Regression ACS Trial

> **NCT02484378** · PHASE2 · COMPLETED · sponsor: **Cerenis Therapeutics, SA** · enrollment: 301 (actual)

## Conditions studied

- Acute Coronary Syndromes

## Interventions

- **DRUG:** CER-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02484378
- **Lead sponsor:** Cerenis Therapeutics, SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-11
- **Final completion:** 2016-12
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2019-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02484378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02484378, "CER-001 Atherosclerosis Regression ACS Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02484378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*